CSPC Pharmaceutical (HKG:1093) has received approval to conduct clinical trials of its SYH2046 tablets from the US Food and Drug Administration, a Friday Hong Kong bourse filing said.
The indication for the approval is heart failure after acute myocardial infarction.
The pharmaceutical company had obtained clinical trial approval for the drug from China's National Medical Products Administration in April.